Literature DB >> 26451315

Natural killer cell mediated immunosurveillance of pediatric neuroblastoma.

Michaela Semeraro1, Sylvie Rusakiewicz1, Laurence Zitvogel1, Guido Kroemer2.   

Abstract

Until recently, the pathophysiological impact of natural killer (NK) lymphocytes has been largely elusive. Capitalizing on our previous discovery that NK cells mediate immunosurveillance against gastrointestinal stromal tumors (GISTs), we have now investigated the potential influence of immunostimulatory and immunosuppressive isoforms of the NK receptor NKp30 on the fate of infants with neuroblastoma. In three independent cohorts of high-risk neuroblastoma, we observed a similar prognostic impact of the ratio of immunostimulatory vs. immunosuppressive NKp30 isoforms. Patients with high-risk neuroblastoma that are in remission after induction chemotherapy have a higher risk of relapse if their circulating and bone marrow NK cells express the preponderantly immunosuppressive NKp30 C isoform, as determined by a robust RT-PCR-based assay. We also found that neuroblastoma cells express the NKp30 ligand B7-H6, which can be shed from the tumor cells. Elevated soluble B7-H6 levels contained in patient sera inhibited NK functions in vitro and correlated with downregulation of NK-p30 on NK cells, as well as with bone marrow metastasis and chemoresistance. Altogether, these results support the contention that NK cells play a decisive role in the immunosurveillance of neuroblastoma. In light of these results, efforts should be undertaken to investigate NK cell functions in all major cancer types, with the obvious expectation of identifying additional NK cell-related prognostic or predictive biomarkers and improving NK cell based immunotherapeutic strategies against cancer.

Entities:  

Keywords:  NK cells; NKp30; immunosurveillance; neuroblastoma; pediatric cancer

Year:  2015        PMID: 26451315      PMCID: PMC4589051          DOI: 10.1080/2162402X.2015.1042202

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  10 in total

1.  Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.

Authors:  Michaela Semeraro; Sylvie Rusakiewicz; Véronique Minard-Colin; Nicolas F Delahaye; David Enot; Frédéric Vély; Aurélien Marabelle; Benjamin Papoular; Christelle Piperoglou; Mirco Ponzoni; Patrizia Perri; Andrei Tchirkov; Jessica Matta; Valérie Lapierre; Tala Shekarian; Sandrine Valsesia-Wittmann; Frédéric Commo; Nicole Prada; Vichnou Poirier-Colame; Brigitte Bressac; Sophie Cotteret; Laurence Brugieres; Françoise Farace; Nathalie Chaput; Guido Kroemer; Dominique Valteau-Couanet; Laurence Zitvogel
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

2.  NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.

Authors:  Sylvie Rusakiewicz; Gaetane Nocturne; Thierry Lazure; Michaela Semeraro; Caroline Flament; Sophie Caillat-Zucman; Damien Sène; Nicolas Delahaye; Eric Vivier; Kariman Chaba; Vichnou Poirier-Colame; Gunnel Nordmark; Maija-Leena Eloranta; Per Eriksson; Elke Theander; Helena Forsblad-d'Elia; Roald Omdal; Marie Wahren-Herlenius; Roland Jonsson; Lars Rönnblom; Joanne Nititham; Kimberly E Taylor; Christopher J Lessard; Kathy L Moser Sivils; Jacques-Eric Gottenberg; Lindsey A Criswell; Corinne Miceli-Richard; Laurence Zitvogel; Xavier Mariette
Journal:  Sci Transl Med       Date:  2013-07-24       Impact factor: 17.956

Review 3.  Innate immune recognition of cancer.

Authors:  Seng-Ryong Woo; Leticia Corrales; Thomas F Gajewski
Journal:  Annu Rev Immunol       Date:  2015-01-22       Impact factor: 28.527

4.  Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.

Authors:  Nicolas F Delahaye; Sylvie Rusakiewicz; Isabelle Martins; Cédric Ménard; Stephan Roux; Luc Lyonnet; Pascale Paul; Matthieu Sarabi; Nathalie Chaput; Michaela Semeraro; Véronique Minard-Colin; Vichnou Poirier-Colame; Kariman Chaba; Caroline Flament; Véronique Baud; Hélène Authier; Saadia Kerdine-Römer; Marc Pallardy; Isabelle Cremer; Laetitia Peaudecerf; Bénédita Rocha; Dominique Valteau-Couanet; Javier Celis Gutierrez; Jacques A Nunès; Frédéric Commo; Sylvie Bonvalot; Nicolas Ibrahim; Philippe Terrier; Paule Opolon; Cristina Bottino; Alessandro Moretta; Jan Tavernier; Pascal Rihet; Jean-Michel Coindre; Jean-Yves Blay; Nicolas Isambert; Jean-François Emile; Eric Vivier; Axel Lecesne; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2011-05-08       Impact factor: 53.440

Review 5.  Innate or adaptive immunity? The example of natural killer cells.

Authors:  Eric Vivier; David H Raulet; Alessandro Moretta; Michael A Caligiuri; Laurence Zitvogel; Lewis L Lanier; Wayne M Yokoyama; Sophie Ugolini
Journal:  Science       Date:  2011-01-07       Impact factor: 47.728

6.  Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.

Authors:  Lucas Ferrari de Andrade; Shin F Ngiow; Kimberley Stannard; Sylvie Rusakiewicz; Murugan Kalimutho; Kum Kum Khanna; Siok-Keen Tey; Kazuyoshi Takeda; Laurence Zitvogel; Ludovic Martinet; Mark J Smyth
Journal:  Cancer Res       Date:  2014-10-28       Impact factor: 12.701

7.  Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.

Authors:  Sylvie Rusakiewicz; Michaela Semeraro; Matthieu Sarabi; Mélanie Desbois; Clara Locher; Rosa Mendez; Nadège Vimond; Angel Concha; Federico Garrido; Nicolas Isambert; Loic Chaigneau; Valérie Le Brun-Ly; Patrice Dubreuil; Isabelle Cremer; Anne Caignard; Vichnou Poirier-Colame; Kariman Chaba; Caroline Flament; Niels Halama; Dirk Jäger; Alexander Eggermont; Sylvie Bonvalot; Frédéric Commo; Philippe Terrier; Paule Opolon; Jean-François Emile; Jean-Michel Coindre; Guido Kroemer; Nathalie Chaput; Axel Le Cesne; Jean-Yves Blay; Laurence Zitvogel
Journal:  Cancer Res       Date:  2013-04-16       Impact factor: 12.701

Review 8.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Mark J Smyth; Guido Kroemer
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

9.  Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort.

Authors:  Nicole Prada; Guillemette Antoni; Frédéric Commo; Sylvie Rusakiewicz; Michaela Semeraro; Faroudy Boufassa; Olivier Lambotte; Laurence Meyer; Marie-Lise Gougeon; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

10.  Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.

Authors:  Nathalie Chaput; Caroline Flament; Clara Locher; Mélanie Desbois; Annie Rey; Sylvie Rusakiewicz; Vichnou Poirier-Colame; Patricia Pautier; Axel Le Cesne; Jean-Charles Soria; Angelo Paci; Michelle Rosenzwajg; David Klatzmann; Alexander Eggermont; Caroline Robert; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

  10 in total
  13 in total

Review 1.  The B7 Family Member B7-H6: a New Bane of Tumor.

Authors:  Ying Chen; Jun Mo; Xi Jia; Yang He
Journal:  Pathol Oncol Res       Date:  2017-10-31       Impact factor: 3.201

Review 2.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 3.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

4.  Asymptomatic incidental neuroblastoma in a patient with SH2D1A deficiency.

Authors:  Taumoha Ghosh; Angela Guerrero-Pena; Madhuri Kashyap; Ali G Saad; Chad M Thorson; Asha B Pillai
Journal:  Pediatr Blood Cancer       Date:  2021-08-29       Impact factor: 3.167

5.  Bringing natural killer cells to the clinic.

Authors:  Laura Chiossone; Eric Vivier
Journal:  J Exp Med       Date:  2022-09-06       Impact factor: 17.579

Review 6.  Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer.

Authors:  Hakim Medjouel Khlifi; Sophie Guia; Eric Vivier; Emilie Narni-Mancinelli
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 7.  Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy.

Authors:  Jesus I Luna; Steven K Grossenbacher; William J Murphy; Robert J Canter
Journal:  Expert Opin Biol Ther       Date:  2016-12-23       Impact factor: 4.388

8.  Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.

Authors:  Brittany J Poelaert; Svetlana Romanova; Shelby M Knoche; Madeline T Olson; Bailee H Sliker; Kaitlin Smits; Brittney L Dickey; Alexandra E J Moffitt-Holida; Benjamin T Goetz; Nuzhat Khan; Lynette Smith; Hamid Band; Aaron M Mohs; Donald W Coulter; Tatiana K Bronich; Joyce C Solheim
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

Review 9.  Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.

Authors:  Matthias Peipp; Katja Klausz; Ammelie Svea Boje; Tobias Zeller; Stefan Zielonka; Christian Kellner
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

10.  Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients.

Authors:  Izhar S Batth; Long Dao; Arun Satelli; Abhisek Mitra; Sofia Yi; Hyangsoon Noh; Heming Li; Zachary Brownlee; Shouhao Zhou; Jeffrey Bond; Jing Wang; Jonathan Gill; Giselle S Sholler; Shulin Li
Journal:  Int J Cancer       Date:  2020-06-23       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.